Prospects and advances of PROTAC in the treatment of hematologic malignancies - PubMed
5 hours ago
- #target protein degradation
- #hematologic malignancies
- #PROTAC
- PROTACs (Proteolysis-Targeting Chimeras) are emerging as a promising treatment for hematologic malignancies by degrading target proteins via the ubiquitin-proteasome system.
- Compared to small-molecule inhibitors (SMIs) and CAR-T therapies, PROTACs offer advantages in specificity, target diversity, and overcoming drug resistance.
- Eight PROTAC candidates are currently in clinical trials for hematologic malignancies, with 56 protein targets in pre-clinical stages categorized into seven functional groups.
- The review highlights PROTACs' potential in treating hematologic malignancies and outlines future development directions.